Who Paid My Doc
Michelle Harkins
Pulmonary Disease Albuquerque, NM Medical Doctor
NPI 1104832823 CMS profile 185881
2211 Lomas Blvd Ne, 1 Unm, Msc10 5550, Albuquerque, NM 87106
General payments
$24,440
Research payments
$5,420
Ownership & investment interest
$0
Through program year 2025, Michelle Harkins of Albuquerque, NM is reported in the CMS Open Payments database as having received $24,440 across 31 general payments and $5,420 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,200 | 1 | |
| 2024 | General | $135 | 2 | |
| 2023 | General | $10,885 | 11 | |
| 2022 | General | $149 | 3 | |
| 2020 | General | $8,203 | 5 | |
| 2019 | General | $868 | 9 | |
| 2019 | Research | $5,420 | 6 |
Beside peers
- Michelle Harkins
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Michelle Harkins were reported at $4,200. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Michelle Harkins | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $868 | $377 | $109–$1,340 | $163 |
| 2020 | $8,203 | $230 | $56–$907 | $114 |
| 2021 | $0 | $269 | $68–$1,072 | $132 |
| 2022 | $149 | $390 | $100–$1,457 | $149 |
| 2023 | $10,885 | $419 | $114–$1,659 | $160 |
| 2024 | $135 | $476 | $123–$1,818 | $164 |
| 2025 | $4,200 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
599
Drug cost
$349,596
Branded share of claims
74.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 36 | $138,945 | |
| Nucala Mepolizumab | Brand | 14 | $51,744 | |
| Tezspire Tezepelumab-Ekko | Brand | 12 | $50,188 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 38 | $21,409 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 59 | $15,962 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 35 | $13,442 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 31 | $13,163 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 56 | $11,331 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 20 | $8,473 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 13 | $6,421 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 23 billing codesPaid by Medicare
$16,766
Medicare patients
103
Services billed
180
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 58% | |
| COPD | 44% | |
| Depression | 40% | |
| Diabetes | 39% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 27% | |
| Heart failure | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
37 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in New Mexico
Related records
Pulmonary Disease in New Mexico
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Mexico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.